<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34261085</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1531-6971</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Current opinion in pulmonary medicine</Title>
          <ISOAbbreviation>Curr Opin Pulm Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Update on sarcoidosis guidelines.</ArticleTitle>
        <Pagination>
          <StartPage>484</StartPage>
          <EndPage>489</EndPage>
          <MedlinePgn>484-489</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MCP.0000000000000807</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW">The current review summarizes recent guidance in the diagnosis and management of sarcoidosis. Until recently, the main guidelines were the 1999 International Statement on Sarcoidosis. However, in 2020 two new guidelines were published by the American and British Thoracic Societies. They have a number of key updates and this review aims to summarize these.</AbstractText>
          <AbstractText Label="RECENT FINDINGS">The key findings from 2020 revolve around several themes. First, the need for a histological diagnosis should be supported by a multidisciplinary team approach. When a histological biopsy is needed of the lungs, thought is given to the approach taken for this and to whether an endobronchial ultrasound, endoscopic ultrasound or transbronchial biopsy is needed. Second, information regarding supporting tests including blood biomarkers, lung function and imaging. Third, a section specific to cardiac sarcoidosis. Finally, a summary of guidance for treating sarcoidosis including the need to treat fatigue.</AbstractText>
          <AbstractText Label="SUMMARY">The recent guidance suggests that a histological biopsy is only needed in cases of diagnostic uncertainty or in patients with typical long standing features on imaging. The guidelines also provide a clear pathway on the type of lung biopsy needed depending on the extent of mediastinal or parenchymal involvement. Support is given to steroid regimens and indication for second-line immunosuppression.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Millward</LastName>
            <ForeName>Kate</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Respiratory Sleep and Support Centre, Royal Papworth Hospital.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fiddler</LastName>
            <ForeName>Christine A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thillai</LastName>
            <ForeName>Muhunthan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Curr Opin Pulm Med</MedlineTA>
        <NlmUniqueID>9503765</NlmUniqueID>
        <ISSNLinking>1070-5287</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001999" MajorTopicYN="N">Bronchoscopy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019160" MajorTopicYN="N">Endosonography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012507" MajorTopicYN="Y">Sarcoidosis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017565" MajorTopicYN="Y">Sarcoidosis, Pulmonary</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>14</Day>
          <Hour>20</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34261085</ArticleId>
        <ArticleId IdType="doi">10.1097/MCP.0000000000000807</ArticleId>
        <ArticleId IdType="pii">00063198-202109000-00028</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chen ES, Moller DR. Sarcoidosis – scientific progress and clinical challenges. Nat Rev Rheumatol 2011; 7:457–467.</Citation>
        </Reference>
        <Reference>
          <Citation>American Thoracic Society. Statement on sarcoidosis. Am J Respir Crit Care Med 1999; 160:736–755.</Citation>
        </Reference>
        <Reference>
          <Citation>Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201:e26–e51.</Citation>
        </Reference>
        <Reference>
          <Citation>Thillai M, Atkins CP, Crawshaw A, et al. BTS Clinical Statement on pulmonary sarcoidosis. Thorax 2021; 76:4–20.</Citation>
        </Reference>
        <Reference>
          <Citation>Reich JM. Confirmatory tissue sampling in clinical stage I sarcoidosis. Am J Respir Crit Care Med 2020; 202:1321–1322.</Citation>
        </Reference>
        <Reference>
          <Citation>Reich JM, Brouns MC, O’Connor EA, Edwards MJ. Mediastinoscopy in patients with presumptive stage I sarcoidosis. Chest 1998; 113:147–153.</Citation>
        </Reference>
        <Reference>
          <Citation>Hawtin KE, Roddie ME, Mauri FA, Copley SJ. Pulmonary sarcoidosis: the ‘Great Pretender’. Clin Radiol 2010; 65:642–650.</Citation>
        </Reference>
        <Reference>
          <Citation>Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014; 2:123–130.</Citation>
        </Reference>
        <Reference>
          <Citation>Fahim A, Rosewarne D. Tissue sampling in suspected sarcoidosis: can we avoid mediastinal procedures? Am J Respir Crit Care Med 2020; 202:1321.</Citation>
        </Reference>
        <Reference>
          <Citation>Fahim A, Qasim MM, Rosewarne D. Neck as mediastinal extension: diagnosis of sarcoidosis by core biopsy of cervical lymph nodes. Clin Respir J 2020; 14:16–20.</Citation>
        </Reference>
        <Reference>
          <Citation>Sryma PB, Mittal S, Madan K, et al. Endoscopic ultrasound in the diagnosis of sarcoidosis: a forgotten tool? Am J Respir Crit Care Med 2020; 202:1320–1321.</Citation>
        </Reference>
        <Reference>
          <Citation>Oki M, Saka H, Ando M, et al. Transbronchial vs transesophageal needle aspiration using an ultrasound bronchoscope for the diagnosis of mediastinal lesions. Chest 2015; 147:1259–1266.</Citation>
        </Reference>
        <Reference>
          <Citation>Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885–1889.</Citation>
        </Reference>
        <Reference>
          <Citation>Gupta D, Dadhwal DS, Agarwal R, et al. Endobronchial ultrasound-guided transbronchial needle aspiration vs conventional transbronchial needle aspiration in the diagnosis of sarcoidosis. Chest 2014; 146:547–556.</Citation>
        </Reference>
        <Reference>
          <Citation>Drent M, Mansour K, Linssen C. Bronchoalveolar lavage in sarcoidosis. Semin Respir Crit Care Med 2007; 28:486–495.</Citation>
        </Reference>
        <Reference>
          <Citation>Costabel U. CD4/CD8 ratios in bronchoalveolar lavage fluid: of value for diagnosing sarcoidosis? Eur Respir J 1997; 10:2699–2700.</Citation>
        </Reference>
        <Reference>
          <Citation>Winterbauer RH, Lammert J, Sellami M, et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993; 104:352–361.</Citation>
        </Reference>
        <Reference>
          <Citation>Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11:1305–1323.</Citation>
        </Reference>
        <Reference>
          <Citation>Mehta D, Lubitz SA, Frankel Z, et al. Cardiac Involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 133:1426–1435.</Citation>
        </Reference>
        <Reference>
          <Citation>Kouranos V, Tzelepis GE, Rapti A, et al. Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC Cardiovasc Imaging 2017; 10:1437–1447.</Citation>
        </Reference>
        <Reference>
          <Citation>Kouranos V, Sharma R, Wells AU. Accurate diagnosis of cardiac sarcoidosis needs a multidisciplinary approach. Br J Hosp Med 2016; 77:614–615.</Citation>
        </Reference>
        <Reference>
          <Citation>Jamilloux Y, Maucort-Boulch D, Kerever S, et al. Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis. Eur Respir J 2016; 48:1700–1709.</Citation>
        </Reference>
        <Reference>
          <Citation>Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50:1700465.</Citation>
        </Reference>
        <Reference>
          <Citation>Drent M, Lower EE, de Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40:255–263.</Citation>
        </Reference>
        <Reference>
          <Citation>Atkins C, Wilson AM. Managing fatigue in sarcoidosis – a systematic review of the evidence. Chron Respir Dis 2017; 14:161–173.</Citation>
        </Reference>
        <Reference>
          <Citation>Tan M-S, Yu J-T, Tan C-C, et al. Efficacy and adverse effects of Ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-Analysis. J Alzheimers Dis 2014; 43:589–603.</Citation>
        </Reference>
        <Reference>
          <Citation>Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008; 133:1189–1195.</Citation>
        </Reference>
        <Reference>
          <Citation>Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2013; 45:159–169.</Citation>
        </Reference>
        <Reference>
          <Citation>Naz I, Ozalevli S, Ozkan S, Sahin H. Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: a randomized controlled trial. J Cardiopulm Rehabil Prev 2018; 38:124–130.</Citation>
        </Reference>
        <Reference>
          <Citation>Saketkoo L, Karpinski A, Young J, et al. Feasibility, utility and symptom impact of modified mindfulness training in sarcoidosis. ERJ Open Res 2018; 4:00085-2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Thillai M, Potiphar L, Eberhardt C, et al. Obstructive lung function in sarcoidosis may be missed, especially in older white patients. Eur Respir J 2012; 39:775–777.</Citation>
        </Reference>
        <Reference>
          <Citation>Thillai M, Chang W, Chaudhuri N, et al. Sarcoidosis in the UK: insights from British Thoracic Society registry data. BMJ Open Respir Res 2019; 6:e000357.</Citation>
        </Reference>
        <Reference>
          <Citation>Thabut G, Mal H. Outcomes after lung transplantation. J Thorac Dis 2017; 9:2684–2691.</Citation>
        </Reference>
        <Reference>
          <Citation>Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381:1718–1727.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34261085</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1531-6971</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Current opinion in pulmonary medicine</Title>
          <ISOAbbreviation>Curr Opin Pulm Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Update on sarcoidosis guidelines.</ArticleTitle>
        <Pagination>
          <StartPage>484</StartPage>
          <EndPage>489</EndPage>
          <MedlinePgn>484-489</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MCP.0000000000000807</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW">The current review summarizes recent guidance in the diagnosis and management of sarcoidosis. Until recently, the main guidelines were the 1999 International Statement on Sarcoidosis. However, in 2020 two new guidelines were published by the American and British Thoracic Societies. They have a number of key updates and this review aims to summarize these.</AbstractText>
          <AbstractText Label="RECENT FINDINGS">The key findings from 2020 revolve around several themes. First, the need for a histological diagnosis should be supported by a multidisciplinary team approach. When a histological biopsy is needed of the lungs, thought is given to the approach taken for this and to whether an endobronchial ultrasound, endoscopic ultrasound or transbronchial biopsy is needed. Second, information regarding supporting tests including blood biomarkers, lung function and imaging. Third, a section specific to cardiac sarcoidosis. Finally, a summary of guidance for treating sarcoidosis including the need to treat fatigue.</AbstractText>
          <AbstractText Label="SUMMARY">The recent guidance suggests that a histological biopsy is only needed in cases of diagnostic uncertainty or in patients with typical long standing features on imaging. The guidelines also provide a clear pathway on the type of lung biopsy needed depending on the extent of mediastinal or parenchymal involvement. Support is given to steroid regimens and indication for second-line immunosuppression.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Millward</LastName>
            <ForeName>Kate</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Respiratory Sleep and Support Centre, Royal Papworth Hospital.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fiddler</LastName>
            <ForeName>Christine A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thillai</LastName>
            <ForeName>Muhunthan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Curr Opin Pulm Med</MedlineTA>
        <NlmUniqueID>9503765</NlmUniqueID>
        <ISSNLinking>1070-5287</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001999" MajorTopicYN="N">Bronchoscopy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019160" MajorTopicYN="N">Endosonography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012507" MajorTopicYN="Y">Sarcoidosis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017565" MajorTopicYN="Y">Sarcoidosis, Pulmonary</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>14</Day>
          <Hour>20</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34261085</ArticleId>
        <ArticleId IdType="doi">10.1097/MCP.0000000000000807</ArticleId>
        <ArticleId IdType="pii">00063198-202109000-00028</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chen ES, Moller DR. Sarcoidosis – scientific progress and clinical challenges. Nat Rev Rheumatol 2011; 7:457–467.</Citation>
        </Reference>
        <Reference>
          <Citation>American Thoracic Society. Statement on sarcoidosis. Am J Respir Crit Care Med 1999; 160:736–755.</Citation>
        </Reference>
        <Reference>
          <Citation>Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201:e26–e51.</Citation>
        </Reference>
        <Reference>
          <Citation>Thillai M, Atkins CP, Crawshaw A, et al. BTS Clinical Statement on pulmonary sarcoidosis. Thorax 2021; 76:4–20.</Citation>
        </Reference>
        <Reference>
          <Citation>Reich JM. Confirmatory tissue sampling in clinical stage I sarcoidosis. Am J Respir Crit Care Med 2020; 202:1321–1322.</Citation>
        </Reference>
        <Reference>
          <Citation>Reich JM, Brouns MC, O’Connor EA, Edwards MJ. Mediastinoscopy in patients with presumptive stage I sarcoidosis. Chest 1998; 113:147–153.</Citation>
        </Reference>
        <Reference>
          <Citation>Hawtin KE, Roddie ME, Mauri FA, Copley SJ. Pulmonary sarcoidosis: the ‘Great Pretender’. Clin Radiol 2010; 65:642–650.</Citation>
        </Reference>
        <Reference>
          <Citation>Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014; 2:123–130.</Citation>
        </Reference>
        <Reference>
          <Citation>Fahim A, Rosewarne D. Tissue sampling in suspected sarcoidosis: can we avoid mediastinal procedures? Am J Respir Crit Care Med 2020; 202:1321.</Citation>
        </Reference>
        <Reference>
          <Citation>Fahim A, Qasim MM, Rosewarne D. Neck as mediastinal extension: diagnosis of sarcoidosis by core biopsy of cervical lymph nodes. Clin Respir J 2020; 14:16–20.</Citation>
        </Reference>
        <Reference>
          <Citation>Sryma PB, Mittal S, Madan K, et al. Endoscopic ultrasound in the diagnosis of sarcoidosis: a forgotten tool? Am J Respir Crit Care Med 2020; 202:1320–1321.</Citation>
        </Reference>
        <Reference>
          <Citation>Oki M, Saka H, Ando M, et al. Transbronchial vs transesophageal needle aspiration using an ultrasound bronchoscope for the diagnosis of mediastinal lesions. Chest 2015; 147:1259–1266.</Citation>
        </Reference>
        <Reference>
          <Citation>Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885–1889.</Citation>
        </Reference>
        <Reference>
          <Citation>Gupta D, Dadhwal DS, Agarwal R, et al. Endobronchial ultrasound-guided transbronchial needle aspiration vs conventional transbronchial needle aspiration in the diagnosis of sarcoidosis. Chest 2014; 146:547–556.</Citation>
        </Reference>
        <Reference>
          <Citation>Drent M, Mansour K, Linssen C. Bronchoalveolar lavage in sarcoidosis. Semin Respir Crit Care Med 2007; 28:486–495.</Citation>
        </Reference>
        <Reference>
          <Citation>Costabel U. CD4/CD8 ratios in bronchoalveolar lavage fluid: of value for diagnosing sarcoidosis? Eur Respir J 1997; 10:2699–2700.</Citation>
        </Reference>
        <Reference>
          <Citation>Winterbauer RH, Lammert J, Sellami M, et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993; 104:352–361.</Citation>
        </Reference>
        <Reference>
          <Citation>Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11:1305–1323.</Citation>
        </Reference>
        <Reference>
          <Citation>Mehta D, Lubitz SA, Frankel Z, et al. Cardiac Involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 133:1426–1435.</Citation>
        </Reference>
        <Reference>
          <Citation>Kouranos V, Tzelepis GE, Rapti A, et al. Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC Cardiovasc Imaging 2017; 10:1437–1447.</Citation>
        </Reference>
        <Reference>
          <Citation>Kouranos V, Sharma R, Wells AU. Accurate diagnosis of cardiac sarcoidosis needs a multidisciplinary approach. Br J Hosp Med 2016; 77:614–615.</Citation>
        </Reference>
        <Reference>
          <Citation>Jamilloux Y, Maucort-Boulch D, Kerever S, et al. Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis. Eur Respir J 2016; 48:1700–1709.</Citation>
        </Reference>
        <Reference>
          <Citation>Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50:1700465.</Citation>
        </Reference>
        <Reference>
          <Citation>Drent M, Lower EE, de Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40:255–263.</Citation>
        </Reference>
        <Reference>
          <Citation>Atkins C, Wilson AM. Managing fatigue in sarcoidosis – a systematic review of the evidence. Chron Respir Dis 2017; 14:161–173.</Citation>
        </Reference>
        <Reference>
          <Citation>Tan M-S, Yu J-T, Tan C-C, et al. Efficacy and adverse effects of Ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-Analysis. J Alzheimers Dis 2014; 43:589–603.</Citation>
        </Reference>
        <Reference>
          <Citation>Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008; 133:1189–1195.</Citation>
        </Reference>
        <Reference>
          <Citation>Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2013; 45:159–169.</Citation>
        </Reference>
        <Reference>
          <Citation>Naz I, Ozalevli S, Ozkan S, Sahin H. Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: a randomized controlled trial. J Cardiopulm Rehabil Prev 2018; 38:124–130.</Citation>
        </Reference>
        <Reference>
          <Citation>Saketkoo L, Karpinski A, Young J, et al. Feasibility, utility and symptom impact of modified mindfulness training in sarcoidosis. ERJ Open Res 2018; 4:00085-2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Thillai M, Potiphar L, Eberhardt C, et al. Obstructive lung function in sarcoidosis may be missed, especially in older white patients. Eur Respir J 2012; 39:775–777.</Citation>
        </Reference>
        <Reference>
          <Citation>Thillai M, Chang W, Chaudhuri N, et al. Sarcoidosis in the UK: insights from British Thoracic Society registry data. BMJ Open Respir Res 2019; 6:e000357.</Citation>
        </Reference>
        <Reference>
          <Citation>Thabut G, Mal H. Outcomes after lung transplantation. J Thorac Dis 2017; 9:2684–2691.</Citation>
        </Reference>
        <Reference>
          <Citation>Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381:1718–1727.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
